TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Placebo Controlled, Double Blind Trial of Metformin in Obese Adolescents.
Brief Summary: This study will determine if the drug metformin, coupled with diet and exercise counseling, will help obese adolescents lose weight.


Options:
A: Arm Label: Sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lead-in sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Sibutramine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Lead-in sibutramine
B: Arm Label: Diet/Exercise only, then Diet/Exercise plus Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Dietary modification with caloric restriction, Behavioral: Establishment of exercise protocol | Arm Label: Diet/Exercise plus Metformin, then Diet/Exercise only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Behavioral: Dietary modification with caloric restriction, Behavioral: Establishment of exercise protocol | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Diet/Exercise only, then Diet/Exercise plus Metformin, Diet/Exercise plus Metformin, then Diet/Exercise only | Intervention Type: BEHAVIORAL; Name: Dietary modification with caloric restriction; Assigned to Arm(s): Diet/Exercise only, then Diet/Exercise plus Metformin, Diet/Exercise plus Metformin, then Diet/Exercise only | Intervention Type: BEHAVIORAL; Name: Establishment of exercise protocol; Assigned to Arm(s): Diet/Exercise only, then Diet/Exercise plus Metformin, Diet/Exercise plus Metformin, then Diet/Exercise only
C: Intervention Type: DRUG; Name: glucophage XR; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Orlistat; Type: EXPERIMENTAL; Interventions: Drug: Orlistat | Intervention Type: DRUG; Name: Orlistat; Assigned to Arm(s): Orlistat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder
Brief Summary: The purpose of this study is to obtain data investigating the safety and efficacy of eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine correlates of PTSD. The investigators hypothesize that eszopiclone will be significantly more effective than placebo and well tolerated for PTSD-related sleep disturbance, improvement in sleep will be associated with improvement in overall PTSD symptoms, and patients with PTSD-related sleep disturbances will have abnormal levels of stress hormones.


Options:
A: Arm Label: Topiramate; Type: EXPERIMENTAL; Interventions: Drug: Topiramate, Drug: placebo control group | Arm Label: Placebo Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo control group | Intervention Type: DRUG; Name: Topiramate; Assigned to Arm(s): Topiramate | Intervention Type: DRUG; Name: placebo control group; Assigned to Arm(s): Placebo Control group, Topiramate
B: Arm Label: Eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): Eszopiclone, Placebo
C: Arm Label: Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine
D: Arm Label: Experimental ketamine group; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Active control midazolam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Experimental ketamine group | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Active control midazolam group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder
Brief Summary: The purpose of this study is to obtain data investigating the safety and efficacy of eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine correlates of PTSD. The investigators hypothesize that eszopiclone will be significantly more effective than placebo and well tolerated for PTSD-related sleep disturbance, improvement in sleep will be associated with improvement in overall PTSD symptoms, and patients with PTSD-related sleep disturbances will have abnormal levels of stress hormones.


Options:
A: Arm Label: Eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): Eszopiclone, Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Eszopiclone 1 mg- Elderly; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 1 mg- Elderly | Arm Label: Eszopiclone 2 mg- Elderly; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 2 mg- Elderly | Arm Label: Eszopiclone 2 mg- Non-elderly; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 2 mg- Non-elderly | Arm Label: Eszopiclone 3 mg- Non-elderly; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 3 mg- Non-elderly | Intervention Type: DRUG; Name: Eszopiclone 1 mg- Elderly; Assigned to Arm(s): Eszopiclone 1 mg- Elderly | Intervention Type: DRUG; Name: Eszopiclone 2 mg- Elderly; Assigned to Arm(s): Eszopiclone 2 mg- Elderly | Intervention Type: DRUG; Name: Eszopiclone 3 mg- Non-elderly; Assigned to Arm(s): Eszopiclone 3 mg- Non-elderly | Intervention Type: DRUG; Name: Eszopiclone 2 mg- Non-elderly; Assigned to Arm(s): Eszopiclone 2 mg- Non-elderly
D: Arm Label: Eszopiclone 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 1 mg | Arm Label: Eszopiclone 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 2 mg | Arm Label: Eszopiclone 3 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 3 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Zolpidem Tartrate 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem Tartrate 10 mg | Intervention Type: DRUG; Name: Eszopiclone 1 mg; Assigned to Arm(s): Eszopiclone 1 mg | Intervention Type: DRUG; Name: Eszopiclone 2 mg; Assigned to Arm(s): Eszopiclone 2 mg | Intervention Type: DRUG; Name: Eszopiclone 3 mg; Assigned to Arm(s): Eszopiclone 3 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Zolpidem Tartrate 10 mg; Assigned to Arm(s): Zolpidem Tartrate 10 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AIM HIGH: Niacin Plus Statin to Prevent Vascular Events
Brief Summary: The purpose of this study is to determine whether raising "good cholesterol" with a drug based on the vitamin niacin, while lowering "bad cholesterol" with a statin drug, can prevent more heart disease than the statin alone.


Options:
A: Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Diet+pravastatin; Assigned to Arm(s): N/A
B: Arm Label: Combination Therapy; Type: EXPERIMENTAL; Interventions: Drug: Extended release niacin, Drug: Simvastatin | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Extended release niacin; Assigned to Arm(s): Combination Therapy | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Combination Therapy, Monotherapy
C: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Aspirin + Atorvastatin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Aspirin + Atorvastatin; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AIM HIGH: Niacin Plus Statin to Prevent Vascular Events
Brief Summary: The purpose of this study is to determine whether raising "good cholesterol" with a drug based on the vitamin niacin, while lowering "bad cholesterol" with a statin drug, can prevent more heart disease than the statin alone.


Options:
A: Arm Label: Extended-release niacin; Type: EXPERIMENTAL; Interventions: Drug: extended-release niacin (Niaspan) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: extended-release niacin (Niaspan) | Intervention Type: DRUG; Name: extended-release niacin (Niaspan); Assigned to Arm(s): Extended-release niacin, Placebo
B: Intervention Type: DRUG; Name: Niacin Extended-Release and simvastatin Tablets; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Extended-Release Niacin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Extended-Release Niacin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Combination Therapy; Type: EXPERIMENTAL; Interventions: Drug: Extended release niacin, Drug: Simvastatin | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Extended release niacin; Assigned to Arm(s): Combination Therapy | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Combination Therapy, Monotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Proton Pump Inhibitor Treatment Stop: Discontinuation of Acid-suppressive Medication Among Long-term Users in a Primary Health Care Setting
Brief Summary: The purpose of this study is to determine how many chronic users of antisecretory medication can stop after a test for a bacteria associated with peptic ulcer disease.

This is evaluated in a discontinuation trial.


Options:
A: Arm Label: 001; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole | Arm Label: 003; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rabeprazole | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Rabeprazole; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): 001
B: Arm Label: Esomeprazole 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Esomeprazole | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole 20 mg, Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR QD | Intervention Type: DRUG; Name: Dexlansoprazole MR QD; Assigned to Arm(s): 1
D: Arm Label: esomeprazole; Type: NO_INTERVENTION; Interventions: Drug: esomeprazole, Procedure: Helicobacter pylori c-13 breath test | Arm Label: placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: esomeprazole, Procedure: Helicobacter pylori c-13 breath test | Intervention Type: DRUG; Name: esomeprazole; Assigned to Arm(s): esomeprazole, placebo drug | Intervention Type: PROCEDURE; Name: Helicobacter pylori c-13 breath test; Assigned to Arm(s): esomeprazole, placebo drug

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery
Brief Summary: The Zilver® PTX™ Drug Eluting Vascular Stent is indicated for the treatment of symptomatic vascular disease of the above-the-knee femoropopliteal artery (ranging from 4 mm to 9 mm in reference vessel diameter) for lesions up to 7 cm long. The clinical trial is stratified by lesion length. The trial will be conducted in 2 phases, with Phase 1 enrolling patients with lesions less than 7 cm long. Phase 2 of the trial will include longer lesions (up to 14 cm long) and will be initiated upon approval by the Food and Drug Administration (FDA).


Options:
A: Arm Label: Paclitaxel-coated balloon; Type: EXPERIMENTAL; Interventions: Device: CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter | Arm Label: Bare balloon; Type: PLACEBO_COMPARATOR; Interventions: Device: Bare Percutaneous Transluminal Angioplasty Balloon Catheter | Intervention Type: DEVICE; Name: CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter; Assigned to Arm(s): Paclitaxel-coated balloon | Intervention Type: DEVICE; Name: Bare Percutaneous Transluminal Angioplasty Balloon Catheter; Assigned to Arm(s): Bare balloon
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Zilver® PTX™ Drug Eluting Vascular Stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty | Intervention Type: DEVICE; Name: Zilver® PTX™ Drug Eluting Vascular Stent; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Angioplasty; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Percutaneous Transluminal Angioplasty | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: LifeStent NT™ Self-Expanding Peripheral Stent | Intervention Type: OTHER; Name: Percutaneous Transluminal Angioplasty; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: LifeStent NT™ Self-Expanding Peripheral Stent; Assigned to Arm(s): 2
D: Arm Label: Rotational Atherectomy + PES; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Rotational Atherectomy + PES | Arm Label: Standard Treatment (PES without Rotational Atherectomy); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Treatment (PES without Rotational Atherectomy) | Intervention Type: PROCEDURE; Name: Rotational Atherectomy + PES; Assigned to Arm(s): Rotational Atherectomy + PES | Intervention Type: PROCEDURE; Name: Standard Treatment (PES without Rotational Atherectomy); Assigned to Arm(s): Standard Treatment (PES without Rotational Atherectomy)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery
Brief Summary: The Zilver® PTX™ Drug Eluting Vascular Stent is indicated for the treatment of symptomatic vascular disease of the above-the-knee femoropopliteal artery (ranging from 4 mm to 9 mm in reference vessel diameter) for lesions up to 7 cm long. The clinical trial is stratified by lesion length. The trial will be conducted in 2 phases, with Phase 1 enrolling patients with lesions less than 7 cm long. Phase 2 of the trial will include longer lesions (up to 14 cm long) and will be initiated upon approval by the Food and Drug Administration (FDA).


Options:
A: Arm Label: Passeo-18 Lux DRB; Type: EXPERIMENTAL; Interventions: Device: Passeo-18 Lux DRB | Arm Label: Standard PTA (POBA); Type: ACTIVE_COMPARATOR; Interventions: Device: Standard PTA (POBA) | Intervention Type: DEVICE; Name: Passeo-18 Lux DRB; Assigned to Arm(s): Passeo-18 Lux DRB | Intervention Type: DEVICE; Name: Standard PTA (POBA); Assigned to Arm(s): Standard PTA (POBA)
B: Arm Label: Stent; Type: EXPERIMENTAL; Interventions: Device: Zilver® PTX™ Stent | Intervention Type: DEVICE; Name: Zilver® PTX™ Stent; Assigned to Arm(s): Stent
C: Arm Label: Moxy Drug Coated Balloon; Type: EXPERIMENTAL; Interventions: Device: Moxy Drug Coated Balloon | Arm Label: Standard Uncoated Angioplasty Balloon; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Uncoated Angioplasty Balloon | Intervention Type: PROCEDURE; Name: Standard Uncoated Angioplasty Balloon; Assigned to Arm(s): Standard Uncoated Angioplasty Balloon | Intervention Type: DEVICE; Name: Moxy Drug Coated Balloon; Assigned to Arm(s): Moxy Drug Coated Balloon
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Zilver® PTX™ Drug Eluting Vascular Stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty | Intervention Type: DEVICE; Name: Zilver® PTX™ Drug Eluting Vascular Stent; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Angioplasty; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial to Determine the Efficacy of Early Versus Standard Antiretroviral Therapy in HIV Infected Adults With CD4+ T Cell Counts Between 200 and 350 Cells/mm3
Brief Summary: Anti-HIV treatment consisting of lamivudine/zidovudine (3TC/ZDV) and efavirenz (EFV) is the current standard of care for initial treatment of HIV in most areas of the world. The purpose of this study is to determine the best time to start this anti-HIV treatment in treatment-naive adults in Haiti.


Options:
A: Arm Label: I; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiretroviral medications | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: Antiretroviral medications+Isoniazid prophylaxis | Arm Label: III; Type: EXPERIMENTAL; Interventions: Drug: Antiretroviral medications | Arm Label: IV; Type: EXPERIMENTAL; Interventions: Drug: Antiretroviral medications+Isoniazid prophylaxis | Intervention Type: DRUG; Name: Antiretroviral medications; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Antiretroviral medications+Isoniazid prophylaxis; Assigned to Arm(s): II | Intervention Type: DRUG; Name: Antiretroviral medications; Assigned to Arm(s): III | Intervention Type: DRUG; Name: Antiretroviral medications+Isoniazid prophylaxis; Assigned to Arm(s): IV
B: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Combined Intervention Strategy; Type: EXPERIMENTAL; Interventions: Procedure: POC (point-of-care) CD4+ (cluster of differentiation 4) Count, Procedure: Accelerated ART (antiretroviral therapy) Initiation, Behavioral: Basic Care and Prevention Package, Behavioral: Cellular Appointment Reminders and Follow-Up, Other: Financial Incentive | Intervention Type: PROCEDURE; Name: POC (point-of-care) CD4+ (cluster of differentiation 4) Count; Assigned to Arm(s): Combined Intervention Strategy | Intervention Type: PROCEDURE; Name: Accelerated ART (antiretroviral therapy) Initiation; Assigned to Arm(s): Combined Intervention Strategy | Intervention Type: BEHAVIORAL; Name: Basic Care and Prevention Package; Assigned to Arm(s): Combined Intervention Strategy | Intervention Type: BEHAVIORAL; Name: Cellular Appointment Reminders and Follow-Up; Assigned to Arm(s): Combined Intervention Strategy | Intervention Type: OTHER; Name: Financial Incentive; Assigned to Arm(s): Combined Intervention Strategy
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Efavirenz, Drug: Lamivudine/Zidovudine | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz, Drug: Lamivudine/Zidovudine | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Lamivudine/Zidovudine; Assigned to Arm(s): A, B
D: Arm Label: Early antiretroviral therapy; Type: EXPERIMENTAL; Interventions: Other: Early antiretroviral therapy | Arm Label: Standard antiretroviral therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early antiretroviral therapy; Assigned to Arm(s): Early antiretroviral therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes
Brief Summary: The purpose of this study is to assess the long term safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.


Options:
A: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
B: Arm Label: Metformin,lifestyle counselling; Type: ACTIVE_COMPARATOR; Interventions: Drug: rosiglitazone, Drug: metformin, Drug: Anti-diabetic medications | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): Metformin,lifestyle counselling | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Metformin,lifestyle counselling | Intervention Type: DRUG; Name: Anti-diabetic medications; Assigned to Arm(s): Metformin,lifestyle counselling
C: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin
D: Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Insulin Lispro | Arm Label: 0.75 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Insulin Lispro | Arm Label: Insulin Glargine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine, Drug: Insulin Lispro | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Insulin Glargine | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265 | Intervention Type: DRUG; Name: Insulin Lispro; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265, Insulin Glargine

Answer: A